EVALUATION OF ELBASVIR AND GRAZOPREVIR EFFECTIVENESS IN THE TREATMENT OF CHRONIC HEPATITIS C
Abstract
Background. Chronic hepatitis C (CHC) remains a significant health issue that requires effective treatment approaches. The incidence of CHC in Russia amounted to 34.86 per 100 thousand population in 2024, more than half of the patients having HCV genotype 1. Objective. To evaluate the effectiveness of the direct-acting antiviral drug grazoprevir + elbasvir in patients with HCV genotype 1. Material and methods. The study involved 93 patients with HCV genotype 1, confirmed by ELISA and PCR, aged 18 to 77 years who were treated in the Day patient facility of the Kirov Infectious Diseases Clinical Hospital in 2024. All patients received combination therapy with grazoprevir 100 mg + elbasvir 50 mg for 8 and 12 weeks. Results. The age of patients with CHC was 60 years (47; 65). 5.4% of patients underwent pegylated interferon and ribavirin therapy. The viral load was 1.3×106 (1.6×105; 1.4×106) IU/mL. After the therapy, all patients showed a biochemical response. Liver enzymes decreased significantly: ALT 40 (21.8; 70.5) – 16 (12.6; 22) U/L, AST 37 (26.8; 61.3) – 20 (17.2; 27.4) U/L. Other parameters were within normal ranges. Conclusion. A sustained virological response was obtained in 99% of cases after antiviral therapy in patients with HCV genotype 1, regardless of the liver fibrosis stage and compensated liver cirrhosis.
References
Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244(4902):359-362. https://doi.org/10.1126/science.2523562.
World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries [Internet]. Available from: https://www.who.int/publications/i/item/9789240091672
Federalnaja sluzhba po nadzoru v sfere zashhity prav potrebitelej i blagopoluchija cheloveka [Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing]. O sostojanii sanitarno-jepidemiologicheskogo blagopoluchija naselenija v Rossijskoj Federacii v 2024 godu: Gosudarstvennyj doklad [Internet]. Moscow; 2025. 424 p. Available from: https://rospotrebnadzor.ru/upload/iblock/b8a/u6lsxjabw032jkdf837nlaezxu3ue09m/GD_SEB.pdf (Russian).
Ministerstvo zdravoohranenija i socialnogo razvitija Rossijskoj Federacii [Ministry of Health of the Russian Federation]. Hronicheskij virusnyj gepatit C: Klinicheskie rekomendacii [Internet]. 2021. Available from: https://cr.minzdrav.gov.ru/view-cr/516_2 (Russian).
Krasavtsev EL, Mitsura VM, Demchilo AP. Jeffektivnost razlichnyh shem terapii preparatami interferonov u pacientov s hronicheskim gepatitom C [Efficiency of various schemes of interferon therapy in patients with chronic hepatitis С]. Problemy zdorovja i jekologii [Health and Ecology Issues]. 2011;1(27):90-95. https://doi.org/10.51523/2708-6011.2011-8-1-17. https://www.elibrary.ru/abvuhv. (Russian).
McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. The New England journal of medicine. 1998;339(21):1485-1492. https://doi.org/10.1056/NEJM199811193392101.
Bogomolov PO, Koblov SV, Buyeverov AO, Matsiyevich MV, Kuzmina OS, Barsukova NA, Dubinina NV. Pegilirovannyj interferon α2a v lechenii hronicheskogo gepatita C [Pegilated interferon α2а in treatment of chronic hepatitis C]. Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii [Russian Journal of Gastroenterology, Hepatology, Coloproctology]. 2012;22(5):64-68. PIWEEL(Russian).
Nikitin IG. Sovremennye podhody k bezinterferonovoj protivovirusnoj terapii hronicheskogo virusnogo gepatita C [Modern Approaches to Interferon-free Antiviral Therapy of Chronic Viral Hepatitis C]. Lechebnoe delo [The Journal of General Medicine]. 2021;(2):121-128. https://doi.org/10.24412/2071-5315-2021-12339. https://www.elibrary.ru/knqzta. (Russian).
Raedler LA. Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection. American health & drug benefits. 2015;8(Spec Feature):142-147.
Bondarenko AL, Fursova EA, Kolupaev SJu. Bezinterferonovaja terapija u pacientov s hronicheskim gepatitom C v realnoj klinicheskoj praktike [Interferon-free therapy in patients with chronic hepatitis C in real clinical practice]. Gepatologija i gastrojenterologija [Hepatology and Gastroenterology]. 2017;1(1):58-63. edn: YXGTAO (Russian).
Znoyko OO. Prakticheskie aspekty primenenija pervoj bezinterferonovoj shemy lechenija hronicheskogo gepatita C v Rossii – SD-terapija (paritaprevir/ritonavir + ombitasvir + dasabuvir) [Practical aspects of the first interferon-free treatment regimen for chronic hepatitis C in Russia – 3D-therapy (paritaprevir /ritonavir + ombitasvir + dasabuvir)]. Infekcionnye bolezni: Novosti. Mnenija. Obuchenie [Infectious deseases: News. Opinions. Training]. 2015;3(12):96-103. edn: UKLLED. (Russian).
Zeuzem S, Serfaty L, Vierling J, Cheng W, George J, Sperl J, Strasser S, Kumada H, Hwang P, Robertson M, Wahl J, Barr E, Talwani R, Platt H. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. Journal of gastroenterology. 2018;53(5):679-688. https://doi.org/10.1007/s00535-018-1429-3.
Cada DJ, Kim AP, Baker DE. Elbasvir/Grazoprevir. Hospital Pharmacy. 2016;51(8):665-686. https://doi.org/10.1310/hpj5108-665.
Wei L, Jia JD, Duan ZP, Wang FS, Niu JQ, Xie W, Huang WX, Zhang MX, Huang Y, Wang MR, Wu SM, Zhao YR, Jia ZS, Zhao XM, Mu SM, Liang LW, Wang Z, Puenpatom A, Hwang P, Robertson MN, Ingravallo P, Asante-Appiah E, Wei B, Evans B, Hanna GJ, et al. Efficacy and safety of elbasvir/grazoprevir in treatment-naive Chinese adults with hepatitis C virus infection: A randomized trial. JGH Open. 2020;4(6):1065-1073. https://doi.org/10.1002/jgh3.12387
Valutite DE, Semenov AV, Ostankova YuV, Kozlov KV, Borisov AG, Nazarov VD, Totolian AA. Vyjavlenie mutacij lekarstvennoj ustojchivosti virusa gepatita C u pacientov s nejeffektivnoj terapiej preparatami prjamogo protivovirusnogo dejstvija [Detection of drug resistance mutations of hepatitis C virus in patients with failure of the treatment with direct acting antivirals]. Zhurnal mikrobiologii, jepidemiologii i immunobiologii [Journal of microbiology, epidemiology and immunobiology]. 2021;98(1):18-27. https://doi.org/10.36233/0372-9311-47. https://www.elibrary.ru/aksnkx. (Russian).
1.png)
